Re: Statins and The BMJ
Another trial needing some scrutinity is SPARCL, a stroke-tia secondary prevention trial demonstrating some effect of atorvastatin 80 mg on the recurrence of ischemic stroke. I never found out why the marginal benefits (NNT > 200) of atorvastatin found their way into guidelines.
Another miracle was, why on earth there was there no overall survival benefit of this kind of statin in mostly above 70 stroke patients who should bear their share of IHD etc.
Is there really no difference between the overall effects of "natural" and "synthetic" statins ?
Competing interests: No competing interests